Nexstim Oyj (OHEL:NXTMH) PEG Ratio: N/A (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:NXTMH Nexstim Oyj OHEL:NXTMH
61 GF Score
Price €10.80
GF Value €9.38
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nexstim Oyj PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Nexstim Oyj's PE Ratio without NRI is 0.00. Nexstim Oyj's 5-Year EBITDA growth rate is 0.00%. Therefore, Nexstim Oyj's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Nexstim Oyj's PEG Ratio or its related term are showing as below:



OHEL:NXTMH's PEG Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.87
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Nexstim Oyj  (OHEL:NXTMH) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Nexstim Oyj PEG Ratio Related Terms


Nexstim Oyj PEG Ratio Historical Data

* Premium members only.

The historical data trend for Nexstim Oyj's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexstim Oyj PEG Ratio Chart

Nexstim Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nexstim Oyj Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OHEL:NXTMH vs ABT, SYK, MDT: PEG Ratio Comparison

For the Medical Devices subindustry, Nexstim Oyj's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexstim Oyj PEG Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Nexstim Oyj's PEG Ratio falls into.


OHEL:NXTMH
61GF Score
Nexstim Oyj OHEL:NXTMH
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nexstim Oyj PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Nexstim Oyj's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Nexstim Oyj (OHEL:NXTMH) Overvalued in 2026?

Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued. The current stock price of €10.80 is trading 15.1% above its estimated GF Value™ of €9.38. GuruFocus considers Nexstim Oyj to be Modestly Overvalued.

Key valuation signals for OHEL:NXTMH:

  • PEG Ratio: N/A
  • GF Value™: €9.38 vs. price of €10.80 (15.1% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the OHEL:NXTMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nexstim Oyj Business Description

Other Exchanges 5NX:Germany
Address Elimaenkatu 9 B, Helsinki, FIN, 00510
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
61GF Score

Get the complete analysis for OHEL:NXTMH

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.80
Price
€9.38
GF Value